Patents by Inventor Malgorzata Pupecka
Malgorzata Pupecka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10466252Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: GrantFiled: February 10, 2014Date of Patent: November 5, 2019Assignee: Glaxo Group LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
-
Patent number: 10302655Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: GrantFiled: August 17, 2017Date of Patent: May 28, 2019Assignee: Glaxo Group LimitedInventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
-
Publication number: 20190040148Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: July 27, 2018Publication date: February 7, 2019Inventors: Laurent JESPERS, Malgorzata Pupecka-Swider, Carolyn Enever, Ian Tomlinson
-
Patent number: 10072089Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: December 21, 2016Date of Patent: September 11, 2018Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka-Swider, Carolyn Enever, Ian Tomlinson
-
Publication number: 20180088128Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: August 17, 2017Publication date: March 29, 2018Inventors: Carolyn ENEVER, Laurent JESPERS, Malgorzata PUPECKA-SWIDER, Ian TOMLINSON
-
Publication number: 20170174775Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: ApplicationFiled: December 21, 2016Publication date: June 22, 2017Inventors: Laurent JESPERS, Malgorzata PUPECKA-SWIDER, Carolyn Enever, Ian Tomlinson
-
Patent number: 9562090Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: February 11, 2013Date of Patent: February 7, 2017Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Carolyn Enever, Ian Tomlinson
-
Publication number: 20150284454Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: April 21, 2015Publication date: October 8, 2015Inventors: ELENA DE ANGELIS, CAROLYN ENEVER, HAIQUN LIU, OLIVER SCHON, MALGORZATA PUPECKA-SWIDER
-
Patent number: 9040668Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: GrantFiled: May 20, 2011Date of Patent: May 26, 2015Assignee: Glaxo Group LimitedInventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon, Malgorzata Pupecka-Swider
-
Patent number: 8877186Abstract: The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.Type: GrantFiled: June 3, 2008Date of Patent: November 4, 2014Assignee: Domantis LimitedInventors: Michael Steward, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever, Laurent Jespers, Thil Dinuk Batuwangala
-
Patent number: 8779103Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.Type: GrantFiled: March 24, 2010Date of Patent: July 15, 2014Assignee: Glaxo Group LimitedInventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzata Pupecka-Swider
-
Publication number: 20140193407Abstract: The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.Type: ApplicationFiled: December 6, 2013Publication date: July 10, 2014Applicant: Glaxo Group LimitedInventors: Christopher Herring, Lucy J. Holt, Laurent S. Jespers, Sebastian Mayer, Malgorzata Pupecka-Swider, Bruce J. Hamilton
-
Publication number: 20140187750Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: February 10, 2014Publication date: July 3, 2014Applicant: Glaxo Group LimitedInventors: Carolyn ENEVER, Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson
-
Patent number: 8685895Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: GrantFiled: December 4, 2009Date of Patent: April 1, 2014Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian M Tomlinson
-
Publication number: 20130230519Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-14-10, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: August 12, 2011Publication date: September 5, 2013Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Malgorzata Pupecka-Swider, Oliver Schon
-
Publication number: 20130129746Abstract: The invention relates to improved variants of the anti-serum albumin immunoglobulin single variable domain DOM7h-11, as well as ligands and drug conjugates comprising such variants, compositions, nucleic acids, vectors and hosts.Type: ApplicationFiled: May 20, 2011Publication date: May 23, 2013Inventors: Elena De Angelis, Carolyn Enever, Haiqun Liu, Oliver Schon, Malgorzata Pupecka-Swider
-
Patent number: 8398979Abstract: The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: June 4, 2008Date of Patent: March 19, 2013Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Patent number: 8357780Abstract: The invention relates to anti-IL-1R1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD.Type: GrantFiled: June 3, 2008Date of Patent: January 22, 2013Assignee: Domantis LimitedInventors: Laurent Jespers, Malgorzata Pupecka, Ian Tomlinson, Carolyn Enever
-
Publication number: 20110229458Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.Type: ApplicationFiled: December 4, 2009Publication date: September 22, 2011Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka, Ian M. Tomlinson
-
Publication number: 20110159003Abstract: Disclosed are ligands that have binding specificity for interleukin-4 (IL-4), for interleukin-13 (IL-13), or for IL-4 and IL-13. Also disclosed are methods of using these ligands. In particular, the use of these ligands for treating allergic asthma is described.Type: ApplicationFiled: January 24, 2007Publication date: June 30, 2011Applicant: Domantis LimitedInventors: Ian Tomlinson, Allart Adriaan Stoop, Armin Sepp, Inusha De Silva, Caroline J. Dimech, Malgorzata Pupecka, Rudolf M.T. De Wildt, Philip D. Drew, Steve Holmes